CD248 and non-small cell lung carcinoma: In our previous study, we demonstrated that CD248 expression in NSCLC‐based CAFs was associated with the adverse patient outcomes and clinicopathological features of NSCLC, including tumour differentiation and staging, lymph node metastasis, and tumour‐node‐metastasis (TNM) staging.22